Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival

Table 1

Clinicopathologic characteristics of the stage I/II ovarian cancer patients.

Characteristic	(%)
	All stages,	Stage I, (80%)	Stage II, (20%)
Age at diagnosis
Median/mean	59/57.63	59/56.86	59/60.71
Range	(34–83)	(34–78)	(51–83)
Grade
0	2 (5.7)	2 (7.1)
1	12 (34.3)	10 (35.7)	2 (28.6)
2	8 (22.9)	5 (17.9)	3 (42.9)
3	13 (37.1)	11 (39.3)	2 (28.6)
Histological subtype
Serous	11 (31.4)	9 (32.1)	2 (28.5)
Endometrioid	20 (57.2)	16 (57.2)	4 (57.2)
Clear-cell	4 (11.4)	3 (10.7)	1 (14.3)
Debulking status
Optimal	34 (97.1)	28 (100)	6 (85.7)
Suboptimal	1 (2.9)		1 (14.3)
Response to therapy
CR^a	33 (94.3)	27 (96.4)	6 (85.7)
PD^b	2 (5.7)	1 (3.6)	1 (14.3)
Survival
Ovarian cancer deaths	6 (17.1)	4 (14.3)	2 (28.5)
Total number of deaths	6 (17.1)	4 (14.3)	2 (28.5)

^aComplete response.
^bProgressive disease.